Collectively, our study suggests that aberrant expression of ITGA2 increases ovarian cancer cell proliferation and enhances ovarian cancer cell resistance to albumin paclitaxel through the AKT/FOXO1 signaling axis. This evidence concerns the gene ITGA2 and ovarian carcinoma.